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Abstract This pilot study aimed to investigate whether
mammographic compression procedures might cause
shedding of tumor cells into the circulatory system as
reflected by circulating tumor cell (CTC) count in periph-
eral venous blood samples. From March to October 2012,
24 subjects with strong suspicion of breast malignancy
were included in the study. Peripheral blood samples were
acquired before and after mammography. Enumeration of
CTCs in the blood samples was performed using the
CellSearch system. The pressure distribution over the
tumor-containing breast was measured using thin pressure
sensors. The median age was 66.5 years (range,
51–87 years). In 22 of the 24 subjects, breast cancer was
subsequently confirmed. The difference between the aver-
age mean tumor pressure 6.8 ± 5.3 kPa (range,
1.0–22.5 kPa) and the average mean breast pressure
3.4 ± 1.6 kPa (range, 1.5–7.1 kPa) was statistically sig-
nificant (p \ 0.001), confirming that there was increased
pressure over the tumor. The median pathological tumor
size was 19 mm (range, 9–30 mm). Four subjects (17 %)
were CTC positive before compression and two of these
(8 %) were also CTC positive after compression. A total of
seven CTCs were isolated with a mean size of 8 9 6 lm2
(range of the longest diameter, 5–12 lm). The study sup-
ports the view that mammography is a safe procedure from
the point of view of tumor cell shedding to the peripheral
blood.
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Introduction
Mammography is the gold standard imaging method of the
breast. Compression of the breast during mammography is
performed to improve image quality by increasing breast
tissue separation and reducing scattered radiation, and to
minimize the radiation dose to the breast, which is one of the
most radiosensitive tissues of the female body. For these
reasons, the breast is compressed as much as reasonably
possible to a level just below the patient’s pain threshold or
up to the maximum setting of the machine (generally 200 N).
It has long been discussed whether this applied pressure may
damage a tumor, resulting in shedding of malignant cells into
the circulatory system and whether this in turn will affect the
prognosis [1–3]. Several publications have stressed the need
for caution in cancer surgery, emphasizing the importance of
minimizing tumor manipulation to avoid dissemination of
malignant cells [4–8]. Older studies have found that
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moderate pressure applied to tumors in small animals caused
the number of cancer cells per ml blood to rise drastically or
the incidence of distant metastases to increase compared to
controls [9–12]. This is a relevant concern for mammogra-
phy since the most important and detrimental step in the
progression of breast cancer is the occurrence of metastatic
disease through dissemination of cancer cells to other parts
of the body.
Many critical steps of the metastatic cascade are unclear,
including how malignant cells (possibly due to acquired
features) can give rise to overt metastasis in secondary
organs. One of the first steps in the metastatic process is the
spread of tumor cells into the blood circulation. These
circulating tumor cells (CTCs) have left the primary tumor
and studies have confirmed that the CTC count per unit of
blood is an independent prognostic marker for progression-
free survival and overall survival in several types of cancer
[13–15]. Also, the CTC count in peripheral blood of met-
astatic cancer patients during therapy directly reflects the
patient’s response to therapy [16, 17]. The prognostic role
of CTC in primary (non-metastatic) cancer has not been
widely investigated [18], but a few studies have shown that
the presence of CTCs can predict poor prognosis also in
patients with primary breast cancer [15, 19, 20]. Further-
more, a prospective study by Lucci et al. [21] has shown
that the presence of one or more CTCs predicted both early
recurrence and decreased overall survival in 302 non-
metastatic breast cancer patients independent of prognostic
factors such as tumor size or grade. Franken et al. [22]
included 404 stage I–III patients and showed that the
presence of CTCs (C1/30 ml) was associated with an
increased risk for breast cancer-related death. Thus, the
presence of CTCs seems to be an important prognostic
factor also in women with primary breast cancer.
We hypothesized that damage to a tumor, caused by the
pressure arising from compression of the breast, might
release tumor cells into the blood stream. The aim of this
pilot study was to investigate whether mammographic
compression procedures might cause shedding of tumor
cells as reflected by a relative increase in CTC count in
peripheral blood samples. To examine a possible correla-
tion between the magnitude of the pressure and the CTC
count, we measured the applied pressure to the tumor and
the rest of the breast.
Materials and methods
Study population
Subjects were recruited among patients referred for clinical
mammography as well as from the screening program.
Patients from the clinical practice (below referred to as
symptomatic women) were selected if information on
clinical findings in the referral notes indicated a strong
suspicion of malignancy, e.g., firm mass with dimpling of
the skin. Subjects from the screening program were
selected on the basis of the screening mammogram show-
ing a strong suspicion of malignancy (BIRADS 4 or 5)
requiring recall for further investigation. A total of 24
subjects were included from March to October 2012. Ele-
ven (46 %) of the subjects were symptomatic and 13
(54 %) were asymptomatic. The asymptomatic subjects
had their screening mammogram a median of 14 days
(range, 8–38 days) before the first blood sample was
drawn. The workflow is illustrated in Fig. 1.
The Regional Ethical Review Board at Lund University
(Dnr 314/2011) approved the study. Written informed
consent was obtained from all included patients and all
examinations were voluntary.
Blood sampling and image acquisition
All blood samples were drawn from either a cubital vein
(97 %) or a vein on the dorsal aspect of the hand (3 %).
The first blood sample was drawn immediately before the
mammography examination, but in the symptomatic
patients, after an ultrasound examination using minimal
pressure on the probe. The rationale of the ultrasound was
to confirm the presence of a suspicious lesion (Fig. 1). All
subjects then underwent three projection views of the
breast of interest: craniocaudal (CC), mediolateral oblique
(MLO) ,and lateromedial (LM) using the Siemens
Symptomatic (N=11) Asymptomatic (N=13) 
Ultrasound*
Blood sample 
Mammography &  
pressure measurement 
Blood sample 
*As a first step in the in vestigation the cancer suspicion was verified by an 
ultrasound examination of the tumor area applying as little pressure as possible.  
CTC count 
Fig. 1 Flow chart of the study
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MAMMOMAT Inspiration system (Siemens AG, Erlan-
gen, Germany). In 22/24 (92 %) of the subjects, the pres-
sure distribution was recorded in the CC projection image;
in the remaining two of the subjects (8 %), it was recorded
in the MLO projection image. After completed mammog-
raphy examination, the second blood sample was drawn.
This occurred on average 5.1 min (range 2–14 min) after
the pressure distribution was recorded. All patients under-
went needle biopsy after the above procedures.
Pressure measurement system
The pressure distribution over the compressed breast was
measured using two thin, flexible I-Scan (TekScan Inc.,
South Boston, MA, USA) force-sensing resistor (FSR)
pressure sensors (model 9801). Each sensor is 0.18 mm
thick and has an active area of 76 9 203 mm2, divided into
6 9 16 sensor elements. The sensors were calibrated and
verified before each subject measurement and the sensi-
tivity was set according to previous experience [23]. The
pressure resolution at this setting is roughly 0.14 kPa with
a saturation limit between 30 and 35 kPa. The performance
of the I-Scan system has been verified previously and
evaluated under conditions similar to those used in this
study [23–25].
Pressure distribution acquisition
Two sensors were fastened adjacent to one another
underneath the compression paddle (model 1014011,
dimensions: 28 9 20 9 0.16 cm3) (Fig. 2) for one of the
projection images (see above) and then removed before the
remaining images were acquired because the sensors are
radiopaque (Fig. 3). The pressure image was obtained
using our routine technique in terms of positioning and
compression force. The output from the sensors was stored
and compression force and thickness were recorded as
indicated by the mammographic device. Pressure data and
the corresponding projection images were used to create
composite images (Fig. 3). The pressure column closest to
the chest wall (the first 16 sensor elements) was excluded
from the analysis as this column is usually outside the
mammogram and characterized by high pressure values
due to the inclusion of superficial parts of the chest wall
[23]. A medical physicist (DF) together with an experi-
enced radiologist (IA) decided in consensus which pressure
elements covered the tumor areas.
Enumeration and definition of circulating tumor cells
Enumeration of CTCs in the blood circulation was performed
with the food and drug administration (FDA)-approved
CellSearchmethod (Veridex, Raritan, NJ, USA). Peripheral
blood was drawn into CellSave preservative tubes (7.5 ml)
(Veridex). Two samples were drawn before compression and
two samples after compression to increase the likelihood of
detecting possible CTCs. The first 3–5 ml of each blood
sampling was discarded before the sample for analysis was
collected in order to avoid contamination of skin epithelial
cells. Samples were maintained at room temperature and
processed within 96 h after blood collection. The methodol-
ogy and the precision, accuracy, and reproducibility of CTC
measurements using the CellSearch system have been
described previously [26, 27]. Briefly, antibodies conjugated
to ferro-fluid particles were used to magnetically isolate cells
expressing the epithelial cell adhesion molecule (EpCAM).
Unbound cells were removed and the enriched sample was
fluorescently stained for nucleic acids (DAPI), cytokeratins
(CK 8, 18, and 19), and CD45. Cells with a size of at least
4 lm presenting the phenotype DAPI?/CK?/CD45- were
classified as CTCs. All CTC evaluations were performed at
the Department of Oncology (Clinical Sciences, Lund Uni-
versity, Sweden), by two accredited and independent scorers.
In this study, the presence of one or more CTCs in any of the
two pairs of samples (before and after) was considered CTC
positive [15, 18, 22, 28, 29].
Staging and pathology review
Information on tumor histology, staging, and prognostic
factors was retrieved from pathology reports (Ska˚ne
Fig. 2 Two FSR pressure sensors fastened underneath the compres-
sion paddle
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University Hospital, Malmo¨, Sweden). All patients under-
went primary surgery according to regional guidelines
including mastectomy or breast-conserving surgery as well
as sentinel node biopsy. In patients with metastatic sentinel
node, axillary clearance was performed. The tumor size
was given as the largest measured histologic value of the x-
, y-, and z-axis of the tumor. Axillary node involvement
was classified as positive in the presence of micro- and
macrometastases, as negative in the presence of only iso-
lated tumor cells or no node involvement, or not applicable
(N/A). All tumors were classified as well as graded
according to the Nottingham (Elston/Ellis) grading system.
Multifocal tumors were characterized by multiple foci of
tumor cells found in the same breast quadrant with inter-
vening ordinary stroma. Vascular invasion was determined
by immunohistochemistry (IHC) of CD34 and CD31 (BD
Pharmingen) to detect blood vessels and podoplanin/D2-40
(Signet antibodies) to detect lymphatic vessels. Estrogen
receptor (ER)- and progesterone receptor (PR) positivity
was evaluated by IHC with monoclonal antibodies (Ven-
tana/Roche) with a cutoff for positivity set to [10 %.
Human epidermal growth factor receptor 2 (HER2) status
was determined according to international standards [30].
Ki67 expression was measured with the antibody M1B1
(DAKO) and the cutoff for positivity was set to [20 %
positively stained tumor cells.
Statistical analysis
The number of patients with positive CTCs was too small to
perform any correlation tests or multivariate analysis. A
paired t test was used to determine if there was a statistically
significant difference between the pressure exerted over the
tumor and the surrounding breast parenchyma. A Mann–
Whitney test was used to assess differences between symp-
tomatic and asymptomatic subjects with regard to tumor
characteristics. All analyses were performed using the SPSS
software (version 20; SPSS Inc., Chicago, IL, USA) and
p values\0.05 were considered statistically significant.
Results
Pathology findings
The median age of the subjects was 66.5 years (range,
51–87 years). Of the 24 subjects, 15 (63 %) had invasive
ductal carcinomas (IDC), three (13 %) had invasive lobular
carcinomas (ILC), four (17 %) had other types of carcinoma,
one (4 %) had non-Hodgkin’s lymphoma, and one (4 %) had
a benign cyst (Table 1). The median pathological tumor size
was 19 mm (range, 9–30 mm). Twelve (55 %) of the
malignant breast tumors were histologic grade 1 or 2 and
eight (36 %) were grade 3. Four (18 %) were HER2 positive,
six (27 %) were ER negative, and 11 (50 %) were PR neg-
ative. One (5 %) of the subjects showed vascular invasion
and 13 (59 %) had Ki67 [ 20 %. There were no apparent
differences between tumor characteristics in symptomatic
and asymptomatic women (p [ 0.05), but a trend for larger
tumor sizes was seen in the symptomatic group (p = 0.10).
Pressure
The average applied compression force over the breast with
pressure sensors attached was 105.1 ± 17.6 N (range
54–132 N). The average breast thickness in the same pro-
jection was 45.1 ± 12.2 mm (range 19–73 mm).
The average maximum tumor pressure was 10.1 ± 8.4 kPa
(range 1.0–36.1 kPa) and the average mean tumor pressure was
6.8 ± 5.3 kPa (range 1.0–22.5 kPa). The difference between
the average mean tumor pressure and the average mean breast
pressure 3.4 ± 1.6 kPa (range 1.5–7.1 kPa) was statistically
significant (p \0.001). Thus, the pressure was, on average,
higher over the tumor compared to the rest of the breast and
confirms that there is substantial pressure over the tumor. An
Fig. 3 A 65-year-old woman (subject 4) with a 30-mm, grade 2,
invasive ductal carcinoma. Note the spiculated tumor with retraction
of the nipple-areolar complex. Pressure is shown on a scale from dark
blue (lowest) to dark red (highest). The maximum tumor pressure was
10 kPa (mean tumor pressure, 8.9 kPa). This patient had 1 CTC
before compression and 1 CTC after compression
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example of a composite image with pressure data displayed as a
color overlay is shown in Fig. 3.
CTC evaluation
Four subjects (17 %) were CTC positive before compres-
sion and two of these (8 %) were also CTC positive after
compression. There was no significant difference between
the number of symptomatic (50 %) and asymptomatic
(50 %) subjects with respect to CTC positivity (p [ 0.05).
A total of seven CTCs were isolated in the samples of all
CTC-positive subjects with a mean size of 8 9 6 lm
(range of the longest diameter, 5–12 lm) (Fig. 4). No
relationships could be found between the presence of CTC
and applied pressure or any pathological factors. An
interesting observation, however, is that the two patients
with CTC-positive results before and after compression had
a tumor size above the median (25 and 30 mm, respec-
tively) (Table 1).
Discussion
This study aimed at investigating whether malignant tumor
cells are shed and detectable in peripheral venous blood
during mammographic compression. To the authors’
knowledge, this is the first study investigating this issue. In
this pilot study, we found no evidence of tumor cell
shedding to the peripheral blood, as opposed to a sub-
stantial number of animal studies [9–12], surgery shedding
studies [4–8], and opinions expressed in letters of concern
[1–3] regarding tumor cell shedding following manipula-
tion of the primary tumor. The presence of C1 CTC in
17 % of our subjects is close to the span of other studies
(using different volumes of blood) of primary breast cancer
patients (19–31 %) [15, 18, 20, 22, 31]. We could not find
any relationship between the presence of CTCs and tumor
characteristics (Table 1), which is consistent with other
studies that have also found a lack of correlation between
CTCs and histopathological factors [18, 29, 32]. We



















ER PR HER2 Ki-67
(%)
1 (a) 66 0 0 13 21 - IDC 3 ? - ? ? - 50
2 (a) 70 0 0 7 13 - IDC 3 - - - - - 70
3 (s) 85 0 0 9 NA NA Non-Hodgkin’s
lymphoma
NA NA NA NA NA NA NA
4 (a) 65 1 1 10 30 - IDC 2 - - ? ? - 15
5 (a) 51 0 0 11 19 - Medullary
carcinoma
3 - - - - - 80
6 (a) 51 0 0 10 12 - IDC 2 - - ? ? - 25
7 (s) 83 0 0 4 17 - Intracystic
papillary
carcinoma
2 - NA ? ? - NA
8 (a) 58 1 0 7 13 - IDC 1 - - ? - - 14
9 (a) 61 0 0 1 11 - IDC 3 - - ? ? - 30
10 (s) 85 0 0 14 22 ? IDC 3 - - ? - ? 75
11 (a) 64 0 0 4 9 - Metaplastic
carcinoma
3 - - - - ? 30
12 (s) 87 0 0 12 19 - IDC 2 ? - ? ? - 17
13 (s) 78 0 0 11 25 - IDC 3 - - - - ? 35
14 (s) 77 1 0 3 NA NA Benign cyst NA NA NA NA NA NA NA
15 (a) 63 0 0 20 20 ? IDC 1 - ? ? ? - 15
16 (s) 83 0 0 2 19 - IDC 2 - - ? ? - 21
17 (s) 67 0 0 6 22 ? ILC 2 - - ? ? - 5
18 (s) 58 0 0 36 12 ? IDC 1 - - ? - - 10
19 (a) 63 0 0 24 15 - IDC 2 - - ? - - 45
20 (s) 81 2 1 4 25 ? ILC 3 - - ? - - 24
21 (a) 70 0 0 17 10 ? ILC 1 ? - ? ? - 13
22 (s) 63 0 0 3 25 - IDC 3 - - - - - 80
23 (a) 72 0 0 6 17 - IDC 3 - - ? ? - 25
24 (a) 66 0 0 NA 30 ? Apokrine
carcinoma
2 - - - - - 21
a Asymptomatic, s symptomatic, NA not applicable, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IDC invasive
ductal carcinoma, ILC invasive lobular carcinoma
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assumed that cancers with a medullary growth pattern
including some grade 3 invasive ductal cancers which are
often also well vascularized would be more prone to mi-
croruptures and shedding than cancers with productive
fibrosis like many grade 1 and 2 ductal and lobular cancers.
Our material might be too small to exclude such a possi-
bility; however, our study indicates a low probability of a
major shedding of CTCs to the peripheral venous blood as
a result of mammographic compression.
One (4 %) of our CTC-positive subjects had a benign
cyst. The reported percentages of patients with benign
disease that are CTC positive are between 8 % [26] and
15 % [22]. Whether the presence of CTCs in patients with
benign disease has any predictive value is currently
unclear. It is possible that these cells are either non-
malignant epithelial cells that have been stimulated to
migration by inflammatory cytokines or actual malignant
CTCs released from a pre-malignant lesion as discussed in
benign colon disease [33].
We found that the pressure over the tumor was higher
than over the rest of the breast, which is attributed to the
difference in tissue elasticity between abnormal and normal
tissue structures. The pressure over the tumor from
manipulating the breast during positioning and subsequent
compression is in general quite low. Clinical exams/pal-
pation and spot compression/magnification views would
result in pressures to the tumor exceeding those applied in
the current study [34]. It is plausible that the pressure
applied in the aforementioned experimental studies of
small animals exceeded the pressure applied with mam-
mography. However, it is also clear that a cyst may
occasionally rupture as a result of mammographic com-
pression showing that the pressure is not insignificant [35].
A few concerns regarding the probability to find CTCs
in the present study should be addressed. First, CTC enu-
meration follows a Poisson distribution and is limited by
the sampling error inherent to rare event detection and the
fact that only *0.15 % (7.5 ml) of the total blood volume
(5 l) is sampled in one CellSave preservative tube [26]. In
this study, two samples were collected before and after
compression (30 ml in total) for increased sensitivity.
Second, despite its status as an FDA-approved method, one
limitation of the CellSearch system is that only CTCs
expressing the epithelial marker EpCAM will be detected.
EpCAM is likely to be (partly) downregulated during
epithelial mesenchymal transition (EMT), which is the
process when tumor cells leave the primary tumor to enter
the blood stream [36]. An EpCAM-based method could
thus lack the possibility to identify the most stem-like and
aggressive cancer cells in the blood circulation. Also, cells
in the ‘‘normal-like’’ subgroup of breast cancer sometimes
lack EpCAM expression [37], causing these cells to avoid
detection in many enumeration methods used today. Third,
there exist no reliable data regarding the CTC half-life in
human subjects. Meng et al. [38] estimate the half-life to be
1–2.4 h. The depletion kinetics of circulating prostate
cancer cells were examined by Li et al. [39] and they found
that [70 % of high-metastatic PC-3 cells and \30 % of
low-metastatic LNCaP cells were depleted from the cir-
culation after 1 h following tail vein injection of BALB/c
nude mice. On the other hand, Romsdahl et al. [10] noticed
a very fast depletion of CTCs with 93.6–99.6 % percent
Fig. 4 Example of CTCs from
the subjects with malignant
disease in the study. The
analysis was performed with the
CellSearch system (Veridex)
and cells positive for CK-PE/
DAPI and negative for CD45-
APC/control (right column)
were considered CTCs
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reduction 4 min after tumor manipulation. We collected
our blood samples as fast as possible, on average 5.1 min
after breast compression, limiting the possible half-life
affect. But, there is a risk that we missed the cell seeding
by collecting the samples either within a too short or too
long time frame. In general, the limited knowledge of the
biology of CTCs and the process of metastasis is a limiting
factor in detecting the total number of CTCs present in
cancer patients.
One can speculate about how a bolus of tumor cells to
the blood would affect the patient prognosis. It is known
that a decrease in the number of CTCs in metastatic breast
cancer patients from unfavorable (C5 CTC/7.5 ml of
blood) to favorable (\5 CTC/7.5 ml of blood) improves
survival and could be used as a predictive factor of treat-
ment response [13, 17]. However, only a fraction of the
tumor cells that are shed into the bloodstream are believed
to succeed in establishing secondary tumors [40]. There are
also indications that trapped tumor cells in the lungs are
destroyed due to mechanical aspects such as frictional and
shearing forces [41]. Still, an increase of trapped malignant
cells to the lungs would likely increase the risk of metas-
tasis [11].
The pathways of possible CTCs originating from pri-
mary breast cancers are largely undetermined. In order to
reach the peripheral veins (from where blood was drawn in
this study), CTCs need to pass both the capillaries of the
lungs and the capillary beds of the extremities without
being trapped. This process is poorly understood, as the
size of a CTC is often in the order of 5–12 lm (and
sometimes considerably larger) compared to the capillar-
ies’ internal diameters of around 3–7 lm. In addition,
carcinoma cells are not especially deformable compared to
erythrocytes, making CTCs ill suited for passage [42].
Possible explanations of CTCs bypassing capillaries are
that they become smaller by pinching off large amounts of
cytoplasm or that they travel through arterio-venous shunts
[43]. Thus, we cannot exclude the dissemination of tumor
cells as a result of applied breast compression; however,
the cells might not reach the peripheral blood due to fil-
tration in the capillary beds. For example, grade 3 tumors
in general have larger, polymorphous cells and should thus
have a greater tendency to be trapped in the lung capil-
laries. Animal studies indicate that a majority of cancer
cells injected intravenously are arrested in the microvas-
culature of the lungs [42, 44, 45] and that the passage
through small capillaries is also tumor dependent [46].
Furthermore, the CTC count has been shown to be higher
in the central veins compared to the peripheral veins [47–
49]. As an extension of the current study on the effect of
breast compression, we intend to draw blood from the
superior vena cava in breast cancer patients undergoing
preoperative chemotherapy, in addition to peripheral vein
sampling, in order to assess the sieving of CTCs in the lung
capillaries.
In conclusion, this pilot study supports the view that
mammography is a safe procedure from the point of view
of malignant cell shedding to peripheral blood.
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